MIAMI, Florida, USA | November 18, 2026
InspireMD, Inc. has announced the successful completion of the first U.S. commercial transcarotid artery revascularization (TCAR) procedures using its FDA-approved CGuard® Prime TransCarotid Stent System, marking an important milestone in the company’s U.S. commercial expansion of its carotid stent technology. The procedures follow the U.S. Food and Drug Administration (FDA) approval of the system’s Premarket Approval (PMA) supplement on November 9, 2026. This development expands the clinical application of InspireMD’s proprietary MicroNet™ mesh-covered stent technology to include TCAR procedures, providing physicians with another treatment option for patients requiring carotid artery revascularization.
First Commercial Procedures Mark U.S. Market Expansion
The initial commercial procedures were performed by vascular specialists at three healthcare institutions across the United States. Brett Almond, M.D., performed procedures at Bay Surgical Specialists in the greater Tampa Bay area, Florida; Gregory T. Clabeaux, D.O., at Sisters of Charity Hospital, part of Catholic Health, in Buffalo, New York; and Bradley R. Grimsley, M.D., at Baylor Scott & White in Dallas, Texas. These initial cases represent the transition of the CGuard Prime TransCarotid Stent System from regulatory approval to commercial clinical use in the United States.The CGuard Prime system features a delivery platform designed specifically for transcarotid access, allowing physicians to use InspireMD’s proprietary MicroNet mesh-covered stent technology during TCAR procedures. The technology combines a self-expanding nitinol stent with a permanent protective micromesh designed to provide an additional barrier against embolic particles. The system is used alongside a compatible, FDA-cleared neuroprotection system specified in its approved labeling. This combination enables physicians to access the company’s carotid stent technology through a transcarotid approach while incorporating measures intended to protect the brain during the intervention.
FDA Approval and Clinical Evidence Supporting CGuard Prime
The FDA’s approval of the CGuard Prime TransCarotid Stent System was supported by results from the CGUARDIANS II pivotal clinical trial, a prospective, multicenter, single-arm U.S. study involving 50 pivotal patients across 11 investigational sites. The study evaluated the system during TCAR procedures in patients considered at high surgical risk, using the FDA-cleared ENROUTE Transcarotid Neuroprotection System.According to the reported 30-day study results, the trial achieved 100% acute device success, with no deaths, strokes, myocardial infarctions or stent thrombosis reported during the evaluation period. Complete stent patency was also observed in evaluable patients. These findings supported the regulatory submission and subsequent FDA approval of the device for its specified TCAR indication. The reported outcomes represent findings from the pivotal study and should not be interpreted as a guarantee of clinical outcomes in every patientThe approved indication covers eligible patients at high risk of adverse events from carotid endarterectomy who require carotid revascularization and meet the specific clinical and anatomical criteria outlined in the FDA-approved labeling. The device must be used with the specified embolic protection system, and its use remains subject to the approved indications, contraindications and safety information.
TCAR Market Opportunity and Future Technology Development
The commercial introduction also represents a strategic opportunity for InspireMD in the expanding U.S. carotid intervention market. According to company estimates, more than 35,000 TCAR procedures are performed annually in the United States. With the expanded indication, CGuard Prime can now be used in both carotid artery stenting (CAS) and TCAR procedures, broadening its potential clinical applications and commercial reach. InspireMD estimates that the combined CAS and TCAR markets account for approximately 75,000 carotid stenting procedures annually in the United States.The company is also advancing its broader TCAR technology platform through the development of SwitchGuard™, a proprietary transcarotid neuroprotection system currently being evaluated in the CGUARDIANS III pivotal clinical trial. SwitchGuard remains investigational and is not currently approved for commercial sale in the United States. If it receives future regulatory approval, the technology could complement the CGuard Prime stent system and support the development of a more integrated TCAR solution.Commenting on the commercial milestone, Marvin Slosman, Chief Executive Officer of InspireMD, stated that completing the first commercial TCAR procedures shortly after FDA approval represents a meaningful transition from regulatory achievement to clinical adoption. The company views the initial procedures as the beginning of a new phase in its U.S. commercialization strategy.
The first commercial use of the CGuard Prime TransCarotid Stent System highlights the growing role of advanced medical devices, carotid intervention technologies and minimally invasive vascular procedures in healthcare. The development also demonstrates how regulatory approval, clinical evidence and commercial implementation can contribute to the expansion of innovative medical technologies in the U.S. healthcare market.
Source: InspireMD, press release



